| CXCL12 (SDF-1)/CXCR4 pathway in cancer BA Teicher, SP Fricker Clinical cancer research 16 (11), 2927-2931, 2010 | 1612 | 2010 |
| Overexpression of metallothionein confers resistance to anticancer drugs SL Kelley, A Basu, BA Teicher, MP Hacker, DH Hamer, JS Lazo Science 241 (4874), 1813-1815, 1988 | 845 | 1988 |
| Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib J Murai, SYN Huang, A Renaud, Y Zhang, J Ji, S Takeda, J Morris, ... Molecular cancer therapeutics 13 (2), 433-443, 2014 | 790 | 2014 |
| Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells BA Teicher, JS Lazo, AC Sartorelli Cancer research 41 (1), 73-81, 1981 | 721 | 1981 |
| Hypoxia and drug resistance BA Teicher Cancer and Metastasis Reviews 13, 139-168, 1994 | 683 | 1994 |
| The proteasome inhibitor PS-341 in cancer therapy BA Teicher, G Ara, R Herbst, VJ Palombella, J Adams Clinical Cancer Research 5 (9), 2638-2645, 1999 | 625 | 1999 |
| Tumor evasion of the immune system by converting CD4+ CD25− T cells into CD4+ CD25+ T regulatory cells: role of tumor-derived TGF-β VC Liu, LY Wong, T Jang, AH Shah, I Park, X Yang, Q Zhang, S Lonning, ... The Journal of Immunology 178 (5), 2883-2892, 2007 | 613 | 2007 |
| Antibody–drug conjugates for cancer therapy A Thomas, BA Teicher, R Hassan The Lancet Oncology 17 (6), e254-e262, 2016 | 562 | 2016 |
| Antibody conjugate therapeutics: challenges and potential BA Teicher, RVJ Chari Clinical cancer research 17 (20), 6389-6397, 2011 | 542 | 2011 |
| Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo BA Teicher, TS Herman, SA Holden, Y Wang, MR Pfeffer, JW Crawford, ... Science 247 (4949), 1457-1461, 1990 | 444 | 1990 |
| A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard … K Antman, L Ayash, A Elias, C Wheeler, M Hunt, JP Eder, BA Teicher, ... Journal of clinical oncology 10 (1), 102-110, 1992 | 433 | 1992 |
| The hypoxic tumor cell: a target for selective cancer chemotherapy KA Kennedy, BA Teicher, S Rockwell, AC Sartorelli Biochemical pharmacology 29 (1), 1-8, 1980 | 418 | 1980 |
| Acquired multicellular-mediated resistance to alkylating agents in cancer. H Kobayashi, S Man, CH Graham, SJ Kapitain, BA Teicher, RS Kerbel Proceedings of the National Academy of Sciences 90 (8), 3294-3298, 1993 | 411 | 1993 |
| Characterization of a Human Squamous Carcinoma Cell Line Resistant to cis-Diamminedichloroplatinum(II) BA Teicher, SA Holden, MJ Kelley, TC Shea, CA Cucchi, A Rosowsky, ... Cancer Research 47 (2), 388-393, 1987 | 394 | 1987 |
| Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease BA Teicher, EA Sotomayor, ZD Huang Cancer Research 52 (23), 6702-6704, 1992 | 361 | 1992 |
| Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents BA Teicher, SA Holden, G Ara, EA Sotomayor, ZD Huang, YN Chen, ... International journal of cancer 57 (6), 920-925, 1994 | 357 | 1994 |
| Comprehensive characterization of the published kinase inhibitor set JM Elkins, V Fedele, M Szklarz, KR Abdul Azeez, E Salah, J Mikolajczyk, ... Nature biotechnology 34 (1), 95-103, 2016 | 337 | 2016 |
| Classification of Antineoplastic Treatments by Their Differential Toxicity toward Putative Oxygenated and Hypoxic Tumor Subpopulations in Vivo in the FSaIIC … BA Teicher, SA Holden, A Al-Achi, TS Herman Cancer research 50 (11), 3339-3344, 1990 | 316 | 1990 |
| Tumor models for efficacy determination BA Teicher Molecular cancer therapeutics 5 (10), 2435-2443, 2006 | 292 | 2006 |
| PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer BH Lok, EE Gardner, VE Schneeberger, A Ni, P Desmeules, N Rekhtman, ... Clinical Cancer Research 23 (2), 523-535, 2017 | 290 | 2017 |
